{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:10:01Z","timestamp":1791202201656,"version":"4.2.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.canlet.2010.08.015","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T04:46:42Z","timestamp":1285044402000},"page":"161-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma"],"prefix":"10.1016","volume":"299","author":[{"given":"Linhua","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Tabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Raffeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2010.08.015_b0005","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2010.08.015_b0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade (Bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Invest."},{"key":"10.1016\/j.canlet.2010.08.015_b0015","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2010.08.015_b0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2010.08.015_b0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2010.08.015_b0030","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2010.08.015_b0035","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood.V90.10.4078","article-title":"Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin\u2019s lymphoma","volume":"90","author":"Koduru","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.08.015_b0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"P\u00e9rez-Gal\u00e1n","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.08.015_b0045","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/20959","article-title":"Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC","volume":"399","author":"Shimizu","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2010.08.015_b0050","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1593\/neo.07589","article-title":"Noxa\/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis","volume":"9","author":"Mei","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2010.08.015_b0055","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/1078-0432.CCR-08-0399","article-title":"MDM2 antagonist Nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma","volume":"15","author":"Tabe","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.08.015_b0060","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-08-0150","article-title":"Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage \u2013 independent p53 phosphorylation in mantle cell lymphoma","volume":"14","author":"Jones","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.08.015_b0065","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/leu.2008.348","article-title":"Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma","volume":"23","author":"Drakos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2010.08.015_b0070","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 Mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.08.015_b0075","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 Gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.08.015_b0080","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2010.08.015_b0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/sj.leu.2400555","article-title":"Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin\u2019s lymphomas: functional studies in a cell line (Granta 519)","volume":"11","author":"Jadayel","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2010.08.015_b0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0145-2126(97)00191-4","article-title":"Z-138: a new mature B-cell acute lymphoblastic leukemia cell line from a patient with transformed chronic lymphocytic leukemia","volume":"22","author":"Estrov","year":"1998","journal-title":"Leukemia Res."},{"key":"10.1016\/j.canlet.2010.08.015_b0095","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0145-2126(02)00013-9","article-title":"Establishment and characterization of a new mantle cell lymphoma cell line","volume":"26","author":"Lai","year":"2002","journal-title":"Mino. Leukemia Res."},{"key":"10.1016\/j.canlet.2010.08.015_b0100","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1038\/sj.onc.1208084","article-title":"Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes","volume":"23","author":"Ferrer","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2010.08.015_b0105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","article-title":"Characterization of 4 mantle cell lymphoma cell lines","volume":"127","author":"Amin","year":"2003","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.canlet.2010.08.015_b0110","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1172\/JCI12807","article-title":"Therapeutic targeting of the MEK\/MAPK signal transduction module in acute myeloid leukemia","volume":"108","author":"Milella","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2010.08.015_b0115","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2003-03-0802","article-title":"PML-RAR\u03b1 is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival","volume":"103","author":"Tabe","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.08.015_b0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/leu.2009.212","article-title":"Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1\/Noxa axis","volume":"24","author":"Kojima","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2010.08.015_b0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.canlet.2010.08.015_b0130","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1080\/10428190801910912","article-title":"Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways","volume":"49","author":"Rizzatti","year":"2008","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.canlet.2010.08.015_b0135","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canlet.2010.08.015_b0140","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","author":"Willis","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2010.08.015_b0145","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","article-title":"Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM","volume":"24","author":"Tagawa","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2010.08.015_b0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrc1588","article-title":"Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs","volume":"5","author":"Nakanishi","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2010.08.015_b0155","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1128\/MCB.21.12.3964-3973.2001","article-title":"NF-\u03baB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling","volume":"21","author":"Kreuz","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2010.08.015_b0160","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0092-8674(02)00703-1","article-title":"Missing pieces in the NF-\u03baB puzzle","volume":"109","author":"Ghosh","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2010.08.015_b0165","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1158\/0008-5472.CAN-08-4282","article-title":"KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model","volume":"69","author":"Difeo","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.08.015_b0170","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1158\/1535-7163.MCT-08-1118","article-title":"Alterations in the Noxa\/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737","volume":"8","author":"Hauck","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2010.08.015_b0175","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438351000409X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438351000409X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:29:31Z","timestamp":1759591771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438351000409X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S030438351000409X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2010.08.015","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2010.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}